![](/wp-content/uploads/2022/09/September-28-2022-Blast-Cover-2.png)
$599
Dexcom Invests in Nutromics $14M Series B; Vertex and MaxCyte Partnership for CRISPR/Cas9-based Gene-editing Program
Two cardiometabolic-related news items have been observed: Nutromics announced it raised $14M in a Series B financing round for its wearable diagnostic platform led by Dexcom Ventures, VU Venture Partners, and Artesian Investments; and MaxCyte announced it signed a strategic platform license with Vertex Pharmaceuticals. Below, FENIX provides highlights and insights for the respective new items.